Your session is about to expire
← Back to Search
Deferoxamine for Meningeal Carcinomatosis
Study Summary
This trial is testing the safety of giving deferoxamine (DFO) directly into the CSF to treat leptomeningeal metastasis from solid tumor cancer. The researchers will start with lower doses and increase until they find the highest dose that still causes few or mild side effects. If DFO is found to be safe, the researchers will then test it to see if it is an effective treatment for NSCLC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 212 Patients • NCT00110617Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I am on a treatment for my brain metastases that is currently working.I have not had brain radiation within the last week.I have not undergone whole-brain or craniospinal radiation therapy.My cancer, including lung cancer, has spread to the lining of my brain or spinal cord.My cancer has spread to my brain but is stable elsewhere.I am committed to using effective birth control during the study.I haven't taken any iron removal medications in the last 4 weeks.My cancer has spread to my brain and other parts of my body.My bone marrow and organs are working well.I have a working Ommaya reservoir installed for treatment.I can take care of myself but might not be able to do heavy physical work.My cancer is a solid tumor and it started in my lungs.I have brain metastases at the time of joining the study.I haven't taken ascorbic acid or prochlorperazine in the last 2 weeks.My seizures are under control with medication.
- Group 1: Deferoxamine (DFO)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is participation in this trial open to the public?
"Affirmative. Clinicaltrials.gov displays that this clinical investigation, which was established on December 22nd 2021, is actively recruiting patients. 35 participants must be found across 14 medical sites for the study to move forward."
How many participants are accepted in this experiment?
"Affirmative. According to the information on clinicaltrials.gov, this research is currently recruiting participants. It was originally posted on December 22nd 2021 and was recently updated on October 31st 2022. 35 subjects need to be enrolled from 14 sites in total."
How many centers are facilitating this research program?
"Currently, 14 local sites are welcoming patient enrollment. Besides Montvale, Basking Ridge and Harrison there are 11 other places to consider. To reduce travel times it is recommended that you select the closest clinical trial site to your residence."
Are there any adverse effects associated with Deferoxamine (DFO)?
"Our team at Power has concluded that Deferoxamine (DFO) safety can be gauged to a 1, due to its being in the preliminary stages of clinical trials; limited data exists concerning both efficacy and safety."
Share this study with friends
Copy Link
Messenger